<DOC>
	<DOCNO>NCT00608621</DOCNO>
	<brief_summary>The study evaluate influence physostigmine postoperative period intensive care patient consider pain quality , opioid consumption , hemodynamics mobilisation .</brief_summary>
	<brief_title>Influence Physostigmine Patient-Controlled Analgesia ( PCA ) Postoperative Intensive Care Patients</brief_title>
	<detailed_description>Pain management major concern postoperative period , mostly base opioids . In numerous experimental clinical trial cholinergic mechanism demonstrate play important antinociceptive role . Physostigmine , central cholineresterase inhibitor , show produce analgesia enhance opiate analgesia systemic injection . This action base Âµ-receptor ( opioid ) activity , mostly explain stimulation serotonine ( 5-HT-3 ) receptor . The major withdrawal utilizating physostigmine postoperative care , due short duration action . In present study , examine effect continuous intavenous physostigmine application patient-controlled analgesia piritramide 48 hour compare placebo infusion NaCl . Major concern set consumption analgesic , VAS-pain scale , hemodynamics , mobilisation side effect .</detailed_description>
	<mesh_term>Physostigmine</mesh_term>
	<criteria>Age 1880 year Indication postoperative pain therapy admission ICU ASA IIII Weight 50125 kg Patients willing participate present study Peridural anesthesia pain management Severe leave ventricular function ( EF &lt; 30 % ) Severe/exacerbated COPD ; Asthma ASA IVV Chronic renal insufficiency ( Creatinine &gt; 1,5 mg/dl ) Ulcera ventriculus Known allergy study agent Hb preoperative &lt; 9,5 g/dl Alcohol , drug and/or tablet abuse ( Opioids , NSAR ) Emergency operation Pregnancy Women childbearing age without negative pregnancy test Severe liver disease ( GOT oder GPT &gt; 45 U/L ) Severe neurologica derangement ( e.g . M. Parkinson , Multiple Sklerosis ) History apoplexia &lt; 6 Monate residuum Perioperative myocardial infarction Patients able agree present study Patients refuse participate present study Patients part study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>physostigmine</keyword>
	<keyword>postoperative analgesia</keyword>
	<keyword>pain</keyword>
	<keyword>patient-controlled analgesia</keyword>
	<keyword>Opioid consumption</keyword>
	<keyword>Pain quality ( VAS Score )</keyword>
	<keyword>Hemodynamics</keyword>
	<keyword>Mobilisation</keyword>
	<keyword>Side effect</keyword>
</DOC>